KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), announced that on January 7, 2016, Ronald Barliant and Dr. Cameron Durrant MD, MBA, were elected as independent directors to the board of directors (the “Board”) of the Company, with Dr. Durrant named as Chairman of the Board. In addition, on January 7, 2016, Michael Harrison resigned from the Board.
Mr. Barliant, an attorney who is of counsel with the law firm of Goldberg Kohn in Chicago, IL, previously served as a United States bankruptcy judge for the Northern District of Illinois from 1988 to 2002. Mr. Barliant has also served as adjunct faculty at John Marshall Law School and is a frequent lecturer and author on bankruptcy-related matters.
Dr. Durrant is a senior pharmaceutical/biotech executive, former physician and a pharma company builder and turnaround specialist. Dr. Durrant has previously served in senior roles with blue-chip, global pharma companies and also as a board member, Chairman, CEO, as well as CFO, for both private and public specialty pharma and biotech companies. (Original Source)
Shares of KaloBios Pharmaceuticals closed last Wednesday at $23.59. KBIO has a 1-year high of $45.82 and a 1-year low of $0.44. The stock’s 50-day moving average is $29.29 and its 200-day moving average is $6.55.
On the ratings front, Needham analyst Alan Carr reiterated a Hold rating on KBIO, in a report issued on November 19. According to TipRanks.com, Carr has a total average return of 18.1%, a 49.2% success rate, and is ranked #47 out of 3610 analysts.
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.